Patient outcomes
. | . | GVHD . | . | . | . | . | |
|---|---|---|---|---|---|---|---|
| Patient no. . | Graft rejection . | Acute grade . | Extensive chronic . | Disease response . | Follow-up, days . | Causes of death . | |
| 1 | No | 0 | Yes | CR | > 1073 | ||
| 2 | No | 0 | No | PR | 156† | NRM: Organizing pneumonia secondary to ARDS | |
| 3 | No | 0 | Yes | CR | > 1155 | ||
| 4 | No | 2 | No | CR‡ | 21† | NRM: Pancreatitis | |
| 5 | No | 0 | Yes | CR | > 1105 | ||
| 6 | No | 1 | Yes | CR | > 901 | ||
| 7 | No | 1 | Yes | CR | > 732 | ||
| 8 | No | 0 | Yes | CR | > 749 | ||
| 9 | No | 4 | Yes | CR | 108† | NRM: MOF from grade 4 GVHD | |
| 10 | No | 3 | Yes | CR | 117† | NRM: Aspergillus pneumonia, sepsis, MOF | |
| 11 | No | 4 | No | CR | 53† | NRM: Grade IV GVHD, aspergillosis | |
| 12 | No | 2 | No | Progression | 146† | Progression, Aspergillus pneumonia | |
| 13 | No | 3 | No | CR | > 361 | ||
| 14 | No | 3 | No | CR | > 398 | ||
| 15 | Yes | 0 | No | CR | 202† | NRM: Aspergillus pneumonia | |
| 16 | No | 2 | Yes | CR | > 217 | ||
| 17 | No | 0 | No | Relapse | > 1250 | ||
| 18 | Yes | 2 | Yes | CR | > 1113 | ||
| 19 | No | 2 | Yes | CR | > 1136 | ||
| 20 | No | 2 | Yes | CR | > 915 | ||
| 21 | No | 3 | Yes | CR | > 742 | ||
| 22 | No | 2 | Yes | CR | > 894 | ||
| 23 | No | 4 | No | CR | 70† | NRM: CHF secondary cardiac fibrosis and grade IV GVHD | |
| 24 | No | 1 | Yes | PR | > 577 | ||
| 25 | No | 4 | No | CR | 143† | NRM: Sepsis syndrome secondary to grade IV GVHD | |
| 26 | No | 3 | Yes | CR | > 231 | ||
| 27 | No | 1 | No | CR | > 210 | ||
| 28 | No | 0 | No | CR | > 87 | ||
| 29 | Yes | 0 | No | CR | > 81 | ||
| 30 | No | 2 | Yes | CR | > 102 | ||
| 31 | No | NE | NE | Progression | 10† | Disease progression | |
| 32 | No | 2 | No | CR | > 93 | ||
| 33 | No | NE | NE | Progression | 44† | Disease progression | |
. | . | GVHD . | . | . | . | . | |
|---|---|---|---|---|---|---|---|
| Patient no. . | Graft rejection . | Acute grade . | Extensive chronic . | Disease response . | Follow-up, days . | Causes of death . | |
| 1 | No | 0 | Yes | CR | > 1073 | ||
| 2 | No | 0 | No | PR | 156† | NRM: Organizing pneumonia secondary to ARDS | |
| 3 | No | 0 | Yes | CR | > 1155 | ||
| 4 | No | 2 | No | CR‡ | 21† | NRM: Pancreatitis | |
| 5 | No | 0 | Yes | CR | > 1105 | ||
| 6 | No | 1 | Yes | CR | > 901 | ||
| 7 | No | 1 | Yes | CR | > 732 | ||
| 8 | No | 0 | Yes | CR | > 749 | ||
| 9 | No | 4 | Yes | CR | 108† | NRM: MOF from grade 4 GVHD | |
| 10 | No | 3 | Yes | CR | 117† | NRM: Aspergillus pneumonia, sepsis, MOF | |
| 11 | No | 4 | No | CR | 53† | NRM: Grade IV GVHD, aspergillosis | |
| 12 | No | 2 | No | Progression | 146† | Progression, Aspergillus pneumonia | |
| 13 | No | 3 | No | CR | > 361 | ||
| 14 | No | 3 | No | CR | > 398 | ||
| 15 | Yes | 0 | No | CR | 202† | NRM: Aspergillus pneumonia | |
| 16 | No | 2 | Yes | CR | > 217 | ||
| 17 | No | 0 | No | Relapse | > 1250 | ||
| 18 | Yes | 2 | Yes | CR | > 1113 | ||
| 19 | No | 2 | Yes | CR | > 1136 | ||
| 20 | No | 2 | Yes | CR | > 915 | ||
| 21 | No | 3 | Yes | CR | > 742 | ||
| 22 | No | 2 | Yes | CR | > 894 | ||
| 23 | No | 4 | No | CR | 70† | NRM: CHF secondary cardiac fibrosis and grade IV GVHD | |
| 24 | No | 1 | Yes | PR | > 577 | ||
| 25 | No | 4 | No | CR | 143† | NRM: Sepsis syndrome secondary to grade IV GVHD | |
| 26 | No | 3 | Yes | CR | > 231 | ||
| 27 | No | 1 | No | CR | > 210 | ||
| 28 | No | 0 | No | CR | > 87 | ||
| 29 | Yes | 0 | No | CR | > 81 | ||
| 30 | No | 2 | Yes | CR | > 102 | ||
| 31 | No | NE | NE | Progression | 10† | Disease progression | |
| 32 | No | 2 | No | CR | > 93 | ||
| 33 | No | NE | NE | Progression | 44† | Disease progression | |
HCT indicates hematopoietic cell transplantation; CR, complete remission; PR, partial remission; NRM, nonrelapse mortality; ARDS, acute respiratory distress syndrome; MOF, multiorgan failure; CHF, congestive heart failure; NE, not evaluable.
*Patients 1 through 16 received transplants from an HLA-matched related donor; patients 17 through 33 received transplants from an unrelated donor.
Patient died at indicated follow-up day.
On autopsy.